MARKET

IUGNF

IUGNF

Imugene
OTCPK
0.035
NaN%
Closed 09:30 10/30 EDT
OPEN
--
PREV CLOSE
0.020
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.260
52 WEEK LOW
0.0055
MARKET CAP
19.35M
P/E (TTM)
-0.1575
1D
5D
1M
3M
1Y
5Y
1D
Imugene posts strong azer-cel Phase 1b results, bolsters balance sheet and reshapes leadership
TipRanks · 1d ago
Weekly Report: what happened at IUGNF last week (1019-1023)?
Weekly Report · 4d ago
Weekly Report: what happened at IUGNF last week (1012-1016)?
Weekly Report · 10/19 09:42
Imugene posts strong new responses in Phase 1b azer-cel trial for B-cell malignancies
TipRanks · 10/19 07:28
Weekly Report: what happened at IUGNF last week (1005-1009)?
Weekly Report · 10/12 09:45
Imugene Sets 2026 AGM, Flags Governance and Capital Management Resolutions
TipRanks · 10/09 02:47
Imugene reshapes leadership as it sharpens focus on azer-cel CAR T program
TipRanks · 10/06 23:11
Weekly Report: what happened at IUGNF last week (0928-1002)?
Weekly Report · 10/05 09:45
More
About IUGNF
Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.

Webull offers Imugene Ltd stock information, including OTCPK: IUGNF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IUGNF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IUGNF stock methods without spending real money on the virtual paper trading platform.